Related Experiment Video
Updated: Aug 4, 2026

The Soft Agar Colony Formation Assay
Published on: October 27, 2014
'WNT-er is coming': WNT signalling in chronic lung diseases
H A Baarsma1, M Königshoff1,2
1Comprehensive Pneumology Center, Helmholtz Center Munich, Ludwig Maximilians University Munich, University Hospital Grosshadern, Member of the German Center for Lung Research (DZL), Munich, Germany.
Abstract:
Chronic lung diseases represent a major public health problem with only limited therapeutic options. An important unmet need is to identify compounds and drugs that target key molecular pathways involved in the pathogenesis of chronic lung diseases. Over the last decade, there has been extensive interest in investigating Wingless/integrase-1 (WNT) signalling pathways; and WNT signal alterations have been linked to pulmonary disease pathogenesis and progression. Here, we comprehensively review the cumulative evidence for WNT pathway alterations in chronic lung pathologies, including idiopathic pulmonary fibrosis, pulmonary arterial hypertension, asthma and COPD. While many studies have focused on the canonical WNT/β-catenin signalling pathway, recent reports highlight that non-canonical WNT signalling may also significantly contribute to chronic lung pathologies; these studies will be particularly featured in this review. We further discuss recent advances uncovering the role of WNT signalling early in life, the potential of pharmaceutically modulating WNT signalling pathways and highlight (pre)clinical studies describing promising new therapies for chronic lung diseases.
Insights
Wingless/integrase-1 (WNT) signaling pathway alterations are implicated in chronic lung diseases like fibrosis and COPD. This review highlights WNT
Area of Science:
- Pulmonary Medicine
- Molecular Biology
- Cell Signaling
Background:
- Chronic lung diseases pose significant public health challenges with limited treatments.
- Identifying molecular targets is crucial for developing novel therapies.
- Wingless/integrase-1 (WNT) signaling pathways are increasingly recognized in lung disease pathogenesis.
Purpose of the Study:
- To comprehensively review the role of WNT pathway alterations in chronic lung diseases.
- To highlight the significance of both canonical and non-canonical WNT signaling.
- To discuss therapeutic potential and recent clinical advancements.
Main Methods:
- Literature review of studies on WNT signaling in chronic lung diseases.
- Focus on idiopathic pulmonary fibrosis, pulmonary arterial hypertension, asthma, and COPD.
- Emphasis on recent findings regarding non-canonical WNT pathways.
Main Results:
- Evidence supports WNT pathway alterations in various chronic lung pathologies.
- Both canonical and non-canonical WNT signaling pathways are implicated.
- WNT signaling plays a role early in life and offers therapeutic targets.
Conclusions:
- WNT signaling is a key player in the development and progression of chronic lung diseases.
- Targeting WNT pathways presents a promising therapeutic strategy.
- Further research into WNT modulation could lead to new treatments for lung conditions.
Related Concept Videos
Canonical Wnt Signaling Pathway
Non-Canonical Wnt Signaling Pathways
Non-Canonical Wnt Signaling Pathways
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features
Chronic Obstructive Pulmonary Disease IV: Clinical Manifestations

